Spoken Alpha
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics develops SLK, a novel Nanobody inhibitor of IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis.
MoonLake Immunotherapeutics is a Healthcare company operating in Biotechnology with a $1.06B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MLTX.
$ curl https://api.spokenalpha.com/v1/companies/MLTXFAQ
Spoken Alpha indexes MLTX's earnings call transcripts at https://spokenalpha.com/companies/MLTX. Each call links to attributed speakers and parsed analyst Q&A. MoonLake Immunotherapeutics's own investor relations page is at https://ir.moonlaketx.com/.
MoonLake Immunotherapeutics (MLTX) held its most recent earnings call on 2025-09-29, covering fiscal Q1 2023.
MoonLake Immunotherapeutics (MLTX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.77 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-09 | $-0.84 | $-0.90 | +6.7% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-0.98 | $-0.92 | -6.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.92 | $-0.98 | +6.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-1.10 | $-0.89 | -23.6% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $-0.87 | $-0.76 | -14.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-0.63 | $-0.74 | +14.3% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.72 | $-0.59 | -22.0% | $101.8K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.56 | $-0.45 | -24.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.39 | $-0.28 | -39.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.22 | $-0.21 | -4.8% | $19.7K | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-0.12 | $-0.23 | +47.8% | $19.7K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.18 | $-0.25 | +28.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.23 | $-0.29 | +20.7% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-0.23 | $-0.31 | +25.8% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-19 | $-0.43 | $-0.28 | -53.6% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.27 | $-0.34 | +20.6% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.34 | $-0.54 | +37.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.35 | $-0.35 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-16 | $-0.15 | — | — | — | — | — | EODHD |
Source: EODHD. MLTX reported actuals as published; sparse fields render as —.